bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables from Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Authors: Zhai Lijie , Ladomersky Erik , Lauing Kristen L. , Wu Meijing , Genet Matthew , Gritsina Galina , Győrffy Balázs , Brastianos Priscilla K. , Binder David C. , Sosman Jeffrey A. , Giles Francis J. , James Charles D. , Horbinski Craig , Stupp Roger , Wainwright Derek A.
Published: April 2023

Description of Supplementary Tables 1-5 that support the expression and clinical relevance of IDO1 in grades II and III glioma, as well as GBM.
Supplementary Tables from Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
Authors: Woods David M. , Ramakrishnan Rupal , Laino Andressa S. , Berglund Anders , Walton Kelly , Betts Brian C. , Weber Jeffrey S.
Published: April 2023

Supplemental Tables
Supplemental Figure 1 from A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
Authors: Schwartzberg Lee S. , Yardley Denise A. , Elias Anthony D. , Patel Manish , LoRusso Patricia , Burris Howard A. , Gucalp Ayca , Peterson Amy C. , Blaney Martha E. , Steinberg Joyce L. , Gibbons Jacqueline A. , Traina Tiffany A.
Published: April 2023

Individual and mean plasma exposures (AUCtau or Cmin) to endocrine therapies alone or in combination with enzalutamide. Note: Box plots provide the mean (red line), median (black line), and 25%/75% quartiles with whiskers to the last point within 1.5-times interquartile range. Sample sizes are reported in Table 2 in the article.
Table S1 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

The mean and median values for checkpoint expression in melanoma
Table S2 from Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Authors: Gallois Claire , Taieb Julien , Le Corre Delphine , Le Malicot Karine , Tabernero Josep , Mulot Claire , Seitz Jean-François , Aparicio Thomas , Folprecht Gunnar , Lepage Côme , Mini Enrico , Van Laethem Jean-Luc , Emile Jean-François , Laurent-Puig Pierre
Published: April 2023

Table S2 shows the comparison of the group assayed for CIMP status and the group not assayed for CIMP status
Supplementary Movie 2 from On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Authors: Brown Benjamin P. , Zhang Yun-Kai , Westover David , Yan Yingjun , Qiao Huan , Huang Vincent , Du Zhenfang , Smith Jarrod A. , Ross Jeffrey S. , Miller Vincent A. , Ali Siraj , Bazhenova Lyudmila , Schrock Alexa B. , Meiler Jens , Lovly Christine M.
Published: April 2023

Supplementary Movie 2
Figure S3 from Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Authors: Gallois Claire , Taieb Julien , Le Corre Delphine , Le Malicot Karine , Tabernero Josep , Mulot Claire , Seitz Jean-François , Aparicio Thomas , Folprecht Gunnar , Lepage Côme , Mini Enrico , Van Laethem Jean-Luc , Emile Jean-François , Laurent-Puig Pierre
Published: April 2023

Figure S3 shows Kaplan-Meier curves according to CIMP status in dMMR group
Supplementary Figures from On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Authors: Brown Benjamin P. , Zhang Yun-Kai , Westover David , Yan Yingjun , Qiao Huan , Huang Vincent , Du Zhenfang , Smith Jarrod A. , Ross Jeffrey S. , Miller Vincent A. , Ali Siraj , Bazhenova Lyudmila , Schrock Alexa B. , Meiler Jens , Lovly Christine M.
Published: April 2023

Supplementary Figures
Supplementary Figure Legends from On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Authors: Brown Benjamin P. , Zhang Yun-Kai , Westover David , Yan Yingjun , Qiao Huan , Huang Vincent , Du Zhenfang , Smith Jarrod A. , Ross Jeffrey S. , Miller Vincent A. , Ali Siraj , Bazhenova Lyudmila , Schrock Alexa B. , Meiler Jens , Lovly Christine M.
Published: April 2023

Supplementary Figure Legends
Supplementary Materials and Methods from PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
Authors: Chung Elaine Y. , Mai Yun , Shah Urvi A. , Wei Yongqiang , Ishida Elise , Kataoka Keisuke , Ren Xiaoxin , Pradhan Kith , Bartholdy Boris , Wei Xiaolei , Zou Yiyu , Zhang Jinghang , Ogawa Seishi , Steidl Ulrich , Zang Xingxing , Verma Amit , Janakiram Murali , Ye B. Hilda
Published: April 2023

Supplementary Materials and Methods
Supplementary Materials from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Supplementary materials
Figure S2 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Figure S2. Receiver operating characteristic (ROC) curves for GC-SVM, clinical stage, clinicopathological characteristics, molecular markers as predictors of 5 years DFS and OS in training and validation cohorts. Left panel: OS; right panel: DFS. The figure showed the top five parameters (with highest AUCs), AUC values and optimal cut-point values. The cut-point of CD34 staining (micro-vessel density, MVD) was the number of micro-vessels per field (Ã-200). The cut-points of immune cells staining in CT and IM were the number of cells per field (Ã-200).
Figure S1 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Figure S1. Representative immunohistochemistry images. IM: invasive margin; CT: core of tumor. Bar, 100 Âµm.
Supplementary Figures from Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
Authors: Ji Changhua , Roy Marc D. , Golas Jonathan , Vitsky Allison , Ram Sripad , Kumpf Steven W. , Martin Matthew , Barletta Frank , Meier William A. , Hooper Andrea T. , Sapra Puja , Khan Nasir K. , Finkelstein Martin , Guffroy Magali , Buetow Bernard S.
Published: April 2023

Supplemental Figure S1. Concentration versus time profiles of ipilimumab and nivolumab following four weekly intravenous dose administrations of 15 mg/kg or 20 mg/kg, respectively. Supplementary Figure S2. Hematoxylin and eosin stained sections of tissues from control and monkeys dosed with ipilimumab and nivolumab. Supplementary Figure S3. Quantification of mononuclear cell infiltrates from IHC images of heart sections.
Table S3- S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Authors: Fan Kaiji , Ritter Cathrin , Nghiem Paul , Blom Astrid , Verhaegen Monique E. , Dlugosz Andrzej , Ødum Niels , Woetmann Anders , Tothill Richard W. , Hicks Rodney J. , Sand Michael , Schrama David , Schadendorf Dirk , Ugurel Selma , Becker Jürgen C.
Published: April 2023

Clinical data of MCC patients from Graz (Table S3), Seattle (Table S4), Essen (Table S5) and Melbourne (Table S6).
Supplementary Methods from Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Authors: Hagemann Urs B. , Ellingsen Christine , Schuhmacher Joachim , Kristian Alexander , Mobergslien Anne , Cruciani Véronique , Wickstroem Katrine , Schatz Christoph A. , Kneip Christoph , Golfier Sven , Smeets Roger , Uran Steinar , Hennekes Hartwig , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Mumberg Dominik , Ziegelbauer Karl , Cuthbertson Alan S.
Published: April 2023

The file contains description of Supporting Methods.
Figure S2 from Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
Authors: Hertz Daniel L. , Kidwell Kelley M. , Vangipuram Kiran , Li Feng , Pai Manjunath P. , Burness Monika , Griggs Jennifer J. , Schott Anne F. , Van Poznak Catherine , Hayes Daniel F. , Lavoie Smith Ellen M. , Henry N. Lynn
Published: April 2023

Supplementary Figure 2: Paclitaxel Exposure in Patients Who Did or Did Not Experience Peripheral Neuropathy-Induced Treatment Disruption. Patients who experienced PN-induced treatment disruption had greater median paclitaxel Tc>0.05 than patients who did not (11 hours (IQR 10-15) vs. 9.5 hours (IQR= 9-11), p=0.001) (left panel). The mean Cmax for patients who experienced treatment disruption was not statistically different from those who did not (2591.8 ng/mL (SD 897.9) vs. 2267.4 ng/mL (SD 521.2), p=0.18). The line in the box is the median. The lower and upper hinges correspond to the first and third quartiles and the lines extend 1.5 x IQR, representing an approximate 95% confidence interval.
Supplementary Data from Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Authors: Toulmonde Maud , Blay Jean-Yves , Bouche Olivier , Mir Olivier , Penel Nicolas , Isambert Nicolas , Duffaud Florence , Bompas Emmanuelle , Esnaud Thomas , Boidot Romain , Geneste Damien , Ghiringhelli François , Lucchesi Carlo , Bellera Carine A. , Le Loarer François , Italiano Antoine
Published: April 2023

Supplementary methods and results
Figure S5 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Quantification of CD31 staining in TBP mice with and without TM treatment.
Supplementary figure and table legend from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Supplementary Figure and Table Legend
Supplementary Table S7. from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

. A complete list of targeted genes in the PI3K/AKT signaling pathway with their associated miRNA from cluster 3.
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Table S2
Supplementary Fig. 8 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Schema for multimodal inhibition in tRCC
Supplementary Fig. 5 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Enriched KEGG PI3K/AKT signaling pathway visualization
Figure S5 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Authors: Marangoni Elisabetta , Laurent Cécile , Coussy Florence , El-Botty Rania , Château-Joubert Sophie , Servely Jean-Luc , de Plater Ludmilla , Assayag Franck , Dahmani Ahmed , Montaudon Elodie , Nemati Fariba , Fleury Justine , Vacher Sophie , Gentien David , Rapinat Audrey , Foidart Pierre , Sounni Nor Eddine , Noel Agnès , Vincent-Salomon Anne , Lae Marick , Decaudin Didier , Roman-Roman Sergio , Bièche Ivan , Piccart Martine , Reyal Fabien
Published: April 2023

Levels of expression for the TYMS, TK1, CCNA2, CCNB1, TOPO2A, TTK, PLK1 and AURKA genes in control and capecitabine-treated xenografts. Mean {plus minus} SD, n=5 xenografts. Statistical significance was determined in multiple t-tests with an alpha risk of 0.05.
Supplementary Data from Hyperspectral Imaging for Resection Margin Assessment during Cancer Surgery
Authors: Kho Esther , de Boer Lisanne L. , Van de Vijver Koen K. , van Duijnhoven Frederieke , Vrancken Peeters Marie-Jeanne T.F.D. , Sterenborg Henricus J.C.M. , Ruers Theo J.M.
Published: April 2023

The four tissue classes, their average spectra before and after SNV normalization and their main differences.
Supplementary Figure 5 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 5
Supplementary Figure 3 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 3
Supplementary Figure S3 from High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling
Authors: Hayashi Takuji , Fujita Kazutoshi , Nojima Satoshi , Hayashi Yujiro , Nakano Kosuke , Ishizuya Yu , Wang Cong , Yamamoto Yoshiyuki , Kinouchi Toshiro , Matsuzaki Kyosuke , Jingushi Kentaro , Kato Taigo , Kawashima Atsunari , Nagahara Akira , Ujike Takeshi , Uemura Motohide , Pena Maria Del Carmen Rodriguez , Gordetsky Jennifer B. , Morii Eiichi , Tsujikawa Kazutake , Netto George J. , Nonomura Norio
Published: April 2023

Relative mRNA expressions and COX2 staining of CD-fed and HFD-fed mice with or without celecoxib / Immune cells of HFD-fed mice with control IgG and anti-IL6 receptor antibody
Liu CCR-18-1236 Revised SD from Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining
Authors: Liu Qi , Ma Lin , Jones Trevor , Palomero Luis , Pujana Miquel Angel , Martinez-Ruiz Haydeliz , Ha Patrick K. , Murnane John , Cuartas Isabel , Seoane Joan , Baumann Michael , Linge Annett , Barcellos-Hoff Mary Helen
Published: April 2023

Supplemental data
Figure S1 from Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine
Authors: Iommelli Francesca , De Rosa Viviana , Terlizzi Cristina , Monti Marcello , Panico Mariarosaria , Fonti Rosa , Del Vecchio Silvana
Published: April 2023

Supplementary Figure S1. Toxicity of combined treatment with erlotinib and crizotinib in H820 cells. Cell toxicity was determined by MTS assay in H820 cells treated with increasing doses of erlotinib and crizotinib used alone or in combination at 1:1 ratio for 72 h. Three independent experiments were performed and data are expressed as mean {plus minus} SE.
Supplementary Figure 1 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Figure 1. Concentration time profiles for AGS-16M8F(Hyb) antibody drug conjugate (ADC) (data is presented as Mean {plus minus} SD)
Supplementary Table S2 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Somatic mutations identified in tissue samples and plasma samples of the enrolled patients
Supplementary Data from Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs
Authors: Vendrell Julie A. , Mazieres Julien , Senal Romain , Rouquette Isabelle , Quantin Xavier , Pujol Jean-Louis , Roch Benoit , Bouidioua Abdelali , Godreuil Sylvain , Coyaud Etienne , Brousset Pierre , Solassol Jérôme
Published: April 2023

Supplementary Figure S1. Flowchart of sample selection criteria. Samples with at least 2 EGFRT790M-positive droplets or greater than 2000 WT-positive droplets detected by ddPCR were retained. These criteria allow a minimum limit of detection of 0.1%. Supplementary Figure S2. Sensitivity and reproducibility of our ddPCR assay for ultra-low EGFRT790M mutation detection. - Supplementary Figure S3. Kaplan-Meier analyses for OS for ultra-low EGFRT790M mutation status in patients treated with first-generation TKIs harboring an EGFRdel19 mutation (A) or the EGFRL858R mutation (B). Supplementary Table S1. Additional patient and specimen characteristics Supplementary Table S2. Determination of the limit of detection of ultra-low EGFRT790M mutation using FFPE tissue samples Supplementary Table S3. Characteristics of patients and specimens with an EGFRactivating mutation according to their ultra-low EGFRT790M mutation status (n = 82) Supplementary Table S4. Description of the region targeted by the amplicon-based panel used in our NGS experiments (Vendrell et al. 2017).
Supplementary Data from Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non–Small Cell Lung Cancer Patients
Authors: Lusk Christine M. , Watza Donovan , Dyson Greg , Craig Douglas , Ratliff Valerie , Wenzlaff Angela S. , Lonardo Fulvio , Bollig-Fischer Aliccia , Bepler Gerold , Purrington Kristen , Gadgeel Shirish , Schwartz Ann G.
Published: April 2023

Tables S1-S6 and Figures S1-S3.
Supplementary Data from Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection
Authors: Tatsuno Kenji , Midorikawa Yutaka , Takayama Tadatoshi , Yamamoto Shogo , Nagae Genta , Moriyama Mitsuhiko , Nakagawa Hayato , Koike Kazuhiko , Moriya Kyoji , Aburatani Hiroyuki
Published: April 2023

Supplementary data 1-8
Supplementary Figure S2 from Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients
Authors: Laban Simon , Gangkofner Dominik S. , Holzinger Dana , Schroeder Lea , Eichmüller Stefan B. , Zörnig Inka , Jäger Dirk , Wichmann Gunnar , Dietz Andreas , Broglie Martina A. , Herold-Mende Christel C. , Dyckhoff Gerhard , Boscolo-Rizzo Paolo , Ezić Jasmin , Marienfeld Ralf , Möller Peter , Kraus Johann M. , Völkel Gunnar , Kestler Hans A. , Brunner Cornelia , Schuler Patrick J. , Wigand Marlene C. , Theodoraki Marie-Nicole , Doescher Johannes , Hoffmann Thomas K. , Pawlita Michael , Waterboer Tim , Butt Julia
Published: April 2023

Overall survival by antibody responses to cancer antigen panel. Overall survival was significantly shorter for patients with {greater than or equal to}2 AR, IMP-1, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A9, p53, Rhodopsin E2 and SSX2. Overall survival was calculated using the Kaplan-Meier method and p-values were determined using logrank tests. Results were corrected for multiple testing with a false discovery rate of 15%.
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 2
Supplementary Data from Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Authors: Lim Su Y. , Lee Jenny H. , Gide Tuba N. , Menzies Alexander M. , Guminski Alexander , Carlino Matteo S. , Breen Edmond J. , Yang Jean Y.H. , Ghazanfar Shila , Kefford Richard F. , Scolyer Richard A. , Long Georgina V. , Rizos Helen
Published: April 2023

Supplementary Table 1: Number of plasma samples included in the study Supplementary Table 2: Association of toxicity with treatment response Supplementary Table 3: Differentially expressed cytokines in patients with severe irAEs compared to those with no-severe irAEs at PRE in Cohort 2 Supplementary Table 4: Differentially expressed cytokines in patients with severe irAEs compared to those with no-severe irAEs at EDT in Cohort 2 Supplementary Table 5: Univariate analysis of cytokine expression and association with overall survival Supplementary Table 6: Univariate analysis of cytokine expression and association with RECIST response Supplementary Figure 1: Distribution of relative fluorescence intensity units of 65 circulating cytokines in plasma collected from 98 melanoma patients (cohorts 1 and 2) prior to therapy initiation. Supplementary Figure 2: Hierarchical clustering of cytokine expression profiles in cohorts 1 and 2.
Table S4 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Characteristics of HBV-infected participants with/without successfully sequenced HBV regions
Supplementary Figure 2 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 2
Supplementary Figure 10 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 10
Supplementary Figure 1 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 1
Supplementary Figure 2 from A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Kahl Brad S. , Hamadani Mehdi , Radford John , Carlo-Stella Carmelo , Caimi Paolo , Reid Erin , Feingold Jay M. , Ardeshna Kirit M. , Solh Melhem , Heffner Leonard T. , Ungar David , He Shui , Boni Joseph , Havenith Karin , O'Connor Owen A.
Published: April 2023

Supplementary Figure 2
Table S1 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Table S1
Supplementary Figure 7 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S7. Additional data on gefitinib and afatinib toxicity analysis in WT and Fanca-deficient mice.
Table S3 from Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
Authors: Qiao Guoliang , Wang Xiaoli , Zhou Lei , Zhou Xinna , Song Yuguang , Wang Shuo , Zhao Lei , Morse Michael A. , Hobeika Amy , Song Jin , Yi Xin , Xia Xuefeng , Ren Jun , Lyerly Herbert Kim
Published: April 2023

Supplementary table 3: Hematological and nonhaematologic adverse events.
Supplementary Table 5 from Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer
Authors: Huang Lei , David Odile , Cabay Robert J. , Valyi-Nagy Klara , Macias Virgilia , Zhong Rong , Wenig Barry , Feldman Lawrence , Weichselbaum Ralph , Spiotto Michael T.
Published: April 2023

Supplemental Table 5. DEmRNAs and DEmiRNAs in LNMs.
Supplementary Table 10 from Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer
Authors: Huang Lei , David Odile , Cabay Robert J. , Valyi-Nagy Klara , Macias Virgilia , Zhong Rong , Wenig Barry , Feldman Lawrence , Weichselbaum Ralph , Spiotto Michael T.
Published: April 2023

Supplemental Table 10. Melanoma characteristics.
Supplementary Data from MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
Authors: Hegi Monika E. , Genbrugge Els , Gorlia Thierry , Stupp Roger , Gilbert Mark R. , Chinot Olivier L. , Nabors L. Burt , Jones Greg , Van Criekinge Wim , Straub Josef , Weller Michael
Published: April 2023

Supplementary Tables and Figures
Supplemenary Figure 7 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure 7
Figure S6 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Figure S6
Figure S5 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Figure S5
Supplemenary Figure 2 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure 2
Figure S3 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Figure S3
Supplementary Table 3 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Tagawa Scott T. , Antonarakis Emmanuel S. , Gjyrezi Ada , Galletti Giuseppe , Kim Seaho , Worroll Daniel , Stewart John , Zaher Atef , Szatrowski Ted P. , Ballman Karla V. , Kita Katsuhiro , Tasaki Shinsuke , Bai Yang , Portella Luigi , Kirby Brian J. , Saad Fred , Eisenberger Mario A. , Nanus David M. , Giannakakou Paraskevi
Published: April 2023

Copy number for AR-V7 and ARv567es stratified by PSA response AR, androgen receptor; IQ, interquartile; PSA50, 50% reduction from baseline in prostate-specific antigen; SD, standard deviation.
Supplementary Tables from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies
Authors: Dylgjeri Emanuela , McNair Christopher , Goodwin Jonathan F. , Raymon Heather K. , McCue Peter A. , Shafi Ayesha A. , Leiby Benjamin E. , de Leeuw Renée , Kothari Vishal , McCann Jennifer J. , Mandigo Amy C. , Chand Saswati N. , Schiewer Matthew J. , Brand Lucas J. , Vasilevskaya Irina , Gordon Nicolas , Laufer Talya S. , Gomella Leonard G. , Lallas Costas D. , Trabulsi Edouard J. , Feng Felix Y. , Filvaroff Ellen H. , Hege Kristin , Rathkopf Dana , Knudsen Karen E.
Published: April 2023

Table S1, Primer sequences used for gene expression analysis. Table S2, PDE pathological characteristics.
Table S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

In vitro activity of PM on histone deacetylase and kinases.
Supplemental Information from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

Supplementary Methods and Supplementary Figure Legends
Supplementary Figure Legends from Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer
Authors: Kregel Steven , Malik Rohit , Asangani Irfan A. , Wilder-Romans Kari , Rajendiran Thekkelnaycke , Xiao Lanbo , Vo Josh N. , Soni Tanu , Cieslik Marcin , Fernadez-Salas Ester , Zhou Bing , Cao Xuhong , Speers Corey , Wang Shaomeng , Chinnaiyan Arul M.
Published: April 2023

Supplementary figure legends
All Supplementary Figures from Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer
Authors: Kregel Steven , Malik Rohit , Asangani Irfan A. , Wilder-Romans Kari , Rajendiran Thekkelnaycke , Xiao Lanbo , Vo Josh N. , Soni Tanu , Cieslik Marcin , Fernadez-Salas Ester , Zhou Bing , Cao Xuhong , Speers Corey , Wang Shaomeng , Chinnaiyan Arul M.
Published: April 2023

All Supplementary figures.
Figure S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Authors: Kieran Mark W. , Geoerger Birgit , Dunkel Ira J. , Broniscer Alberto , Hargrave Darren , Hingorani Pooja , Aerts Isabelle , Bertozzi Anne-Isabelle , Cohen Kenneth J. , Hummel Trent R. , Shen Violet , Bouffet Eric , Pratilas Christine A. , Pearson Andrew D.J. , Tseng Lillian , Nebot Noelia , Green Steven , Russo Mark W. , Whitlock James A.
Published: April 2023

Study design
Figure S6 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S6
Figure S10 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S10
Supplementary Data from The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Authors: Truini Anna , Starrett Jacqueline H. , Stewart Tyler , Ashtekar Kumar , Walther Zenta , Wurtz Anna , Lu David , Park Jin H. , DeVeaux Michelle , Song Xiaoling , Gettinger Scott , Zelterman Daniel , Lemmon Mark A. , Goldberg Sarah B. , Politi Katerina
Published: April 2023

Figures S1-S5
Figure S1 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Authors: Li Li , Jiang Liyan , Wang Yubo , Zhao Yizhuo , Zhang Xiao-Ju , Wu Guoming , Zhou Xiangdong , Sun Jianguo , Bai Jun , Ren Biyong , Tian Kun , Xu Zhi , Xiao Hua-liang , Zhou Qi , Han Rui , Chen Hengyi , Wang Haidong , Yang Zhenzhou , Gao Chan , Cai Shangli , He Yong
Published: April 2023

Kaplan-Meier curves for progression-free survival in subgroups.
Appendix 5 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Authors: van der Voort Sebastian R. , Incekara Fatih , Wijnenga Maarten M.J. , Kapas Georgios , Gardeniers Mayke , Schouten Joost W. , Starmans Martijn P.A. , Nandoe Tewarie Rishie , Lycklama Geert J. , French Pim J. , Dubbink Hendrikus J. , van den Bent Martin J. , Vincent Arnaud J.P.E. , Niessen Wiro J. , Klein Stefan , Smits Marion
Published: April 2023

Results of mixing EMC/HMC and TCIA datasets
Appendix 2 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Authors: van der Voort Sebastian R. , Incekara Fatih , Wijnenga Maarten M.J. , Kapas Georgios , Gardeniers Mayke , Schouten Joost W. , Starmans Martijn P.A. , Nandoe Tewarie Rishie , Lycklama Geert J. , French Pim J. , Dubbink Hendrikus J. , van den Bent Martin J. , Vincent Arnaud J.P.E. , Niessen Wiro J. , Klein Stefan , Smits Marion
Published: April 2023

Radiogenomics algorithm
Appendix 1 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Authors: van der Voort Sebastian R. , Incekara Fatih , Wijnenga Maarten M.J. , Kapas Georgios , Gardeniers Mayke , Schouten Joost W. , Starmans Martijn P.A. , Nandoe Tewarie Rishie , Lycklama Geert J. , French Pim J. , Dubbink Hendrikus J. , van den Bent Martin J. , Vincent Arnaud J.P.E. , Niessen Wiro J. , Klein Stefan , Smits Marion
Published: April 2023

Overview of MR settings
Table S6 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S6 shows the correlation between patients' clinicopathologic parameters and CD66b+ TINs in tumor stroma.
Figure S1 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Figure S1 shows that the abundance of parenchymal TINs is associated with poor prognosis.
Supplementary Data from Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides
Authors: O'Malley John T. , de Masson Adele , Lowry Elizabeth L. , Giobbie-Hurder Anita , LeBoeuf Nicole R. , Larocca Cecilia , Gehad Ahmed , Seger Edward , Teague Jessica E. , Fisher David C. , Kupper Thomas S. , Devlin Phillip M. , Clark Rachael A.
Published: April 2023

Figure S3
Supplementary figure 4 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Isolation of circulating tumour cells from mice treated with IL-1Ra or Canakinumab
Supplementary Table 2 from TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Authors: Rimawi Mothaffar F. , Niravath Polly , Wang Tao , Rexer Brent N. , Forero Andres , Wolff Antonio C. , Nanda Rita , Storniolo Anna M. , Krop Ian , Goetz Matthew P. , Nangia Julie R. , Jiralerspong Sao , Pavlick Anne , Veeraraghavan Jamunarani , De Angelis Carmine , Gutierrez Carolina , Schiff Rachel , Hilsenbeck Susan G. , Osborne C. Kent
Published: April 2023

Characteristics of TBCRC023 Patients with disease progression
Supplementary Data from Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma
Authors: Dong Lei , You Shuo , Zhang Qing , Osuka Satoru , Devi Narra S. , Kaluz Stefan , Ferguson Jalisa H. , Yang Hua , Chen Guoliang , Wang Binghe , Grossniklaus Hans E. , Van Meir Erwin G.
Published: April 2023

Suppl. Table 1
Table S1 from Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Crosby Erika J. , Gwin William , Blackwell Kimberly , Marcom Paul K. , Chang Serena , Maecker Holden T. , Broadwater Gloria , Hyslop Terry , Kim Sungjin , Rogatko Andre , Lubkov Veronica , Snyder Joshua C. , Osada Takuya , Hobeika Amy C. , Morse Michael A. , Lyerly H. Kim , Hartman Zachary C.
Published: April 2023

CYTOF Panel
Supplementary Data from Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma
Authors: Dong Lei , You Shuo , Zhang Qing , Osuka Satoru , Devi Narra S. , Kaluz Stefan , Ferguson Jalisa H. , Yang Hua , Chen Guoliang , Wang Binghe , Grossniklaus Hans E. , Van Meir Erwin G.
Published: April 2023

Suppl. Table 2
Suppl. Fig. Legends from Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma
Authors: Dong Lei , You Shuo , Zhang Qing , Osuka Satoru , Devi Narra S. , Kaluz Stefan , Ferguson Jalisa H. , Yang Hua , Chen Guoliang , Wang Binghe , Grossniklaus Hans E. , Van Meir Erwin G.
Published: April 2023

Suppl. Fig. Legends
Supplementary Data from Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma
Authors: Reid Erin G. , Suazo Adrienne , Lensing Shelly Y. , Dittmer Dirk P. , Ambinder Richard F. , Maldarelli Frank , Gorelick Robert J. , Aboulafia David , Mitsuyasu Ronald , Dickson Mark A. , Wachsman William
Published: April 2023

Supplementary Methods and Figure Supplemental Figure 1. Images demonstrating improvement in KS lesions in two patients obtaining partial response to bortezomib despite receiving treatment in the lowest 2 dose cohorts. Both patients met criteria for partial response after 2 cycles of bortezomib. A. Images for "Patient 2" (dose level 1) demonstrate fading of lesion pigmentation after cycle 2 and further fading after cycle 8; less well-appreciable from photographs is the observed flattening of initially raised lesions. B. After only 2 cycles of bortezomib, "Patient 5" (dose level 2) experienced resolution of several lesions and fading of others.
Table S2 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Authors: Tarlock Katherine , Alonzo Todd A. , Wang Yi-Cheng , Gerbing Robert B. , Ries Rhonda , Loken Michael R. , Pardo Laura , Hylkema Tiffany , Joaquin Jason , Sarukkai Leela , Raimondi Susana C. , Hirsch Betsy , Sung Lillian , Aplenc Richard , Bernstein Irwin , Gamis Alan S. , Meshinchi Soheil , Pollard Jessica A.
Published: April 2023

Supplementary Table 2. Clinical outcomes for patients with CBF AML according to E17+ vs KIT- mutational status
Table S1 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Authors: Tarlock Katherine , Alonzo Todd A. , Wang Yi-Cheng , Gerbing Robert B. , Ries Rhonda , Loken Michael R. , Pardo Laura , Hylkema Tiffany , Joaquin Jason , Sarukkai Leela , Raimondi Susana C. , Hirsch Betsy , Sung Lillian , Aplenc Richard , Bernstein Irwin , Gamis Alan S. , Meshinchi Soheil , Pollard Jessica A.
Published: April 2023

Supplementary Table 1. Clinical and biologic characteristics of CBF patients treated on COG AAML0531 stratified by KIT mutational status.
Table S2 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
Authors: Bernard Vincent , Semaan Alexander , Huang Jonathan , San Lucas F. Anthony , Mulu Feven C. , Stephens Bret M. , Guerrero Paola A. , Huang Yanqing , Zhao Jun , Kamyabi Nabiollah , Sen Subrata , Scheet Paul A. , Taniguchi Cullen M. , Kim Michael P. , Tzeng Ching-Wei , Katz Matthew H. , Singhi Aatur D. , Maitra Anirban , Alvarez Hector A.
Published: April 2023

Cell phenotype gene list
Figure S2 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
Authors: Bernard Vincent , Semaan Alexander , Huang Jonathan , San Lucas F. Anthony , Mulu Feven C. , Stephens Bret M. , Guerrero Paola A. , Huang Yanqing , Zhao Jun , Kamyabi Nabiollah , Sen Subrata , Scheet Paul A. , Taniguchi Cullen M. , Kim Michael P. , Tzeng Ching-Wei , Katz Matthew H. , Singhi Aatur D. , Maitra Anirban , Alvarez Hector A.
Published: April 2023

(A) Gross pathology of a HGD-IPMN lesion with concomitant PDAC included in this study. (B) Paraffin fixed tissue H&E sections of representative LGD-IPMN and HGD-IPMN lesions included in this study (20x magnification).
Supplementary Data from lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP
Authors: Li Nan , Yang Guohua , Luo Liyun , Ling Li , Wang Xiaorong , Shi Lejuan , Lan Junsong , Jia Xiaoting , Zhang Qiong , Long Ze , Liu Jinbao , Hu Weimin , He Zhimin , Liu Haiying , Liu Wanqing , Zheng Guopei
Published: April 2023

Methods and Materials
Supplemental Figure 2 from Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model
Authors: Juthani Rupa , Madajewski Brian , Yoo Barney , Zhang Li , Chen Pei-Ming , Chen Feng , Turker Melik Z. , Ma Kai , Overholtzer Michael , Longo Valerie A. , Carlin Sean , Aragon-Sanabria Virginia , Huse Jason , Gonen Mithat , Zanzonico Pat , Rudin Charles M. , Wiesner Ulrich , Bradbury Michelle S. , Brennan Cameron W.
Published: April 2023

Distribution of targeted (cRGD) and non-targeted (cRAD) C' dots at early (3 hr) timepoints in a genetically-engineered mouse model of glioma.
Table S5 from Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Authors: Yoon Harry H. , Shi Qian , Heying Erica N. , Muranyi Andrea , Bredno Joerg , Ough Faith , Djalilvand Azita , Clements June , Bowermaster Rebecca , Liu Wen-Wei , Barnes Michael , Alberts Steven R. , Shanmugam Kandavel , Sinicrope Frank A.
Published: April 2023

Table S5. Identification of optimal cutpoint in CD3+ T-cell densities at the invasive margin (CD3+IM) to distinguish overall survival in mismatch repair-proficient stage IIII colon cancers